Here is the discipline of this piece: no vibes, no “trust me,” a fixed set of criteria applied the same way to every name on the list. If you are new to AOD-9604 and want a clean answer on where to start, that answer is coming, but it is coming after the method, because the method is the point.
The uncomfortable fact up front, stated once and not softened: AOD-9604’s largest human trial did not beat placebo. 536 people, 24 weeks, no significant weight loss, and the company developing it shut the program down in 2007 [4]. So “safe starting point” in this piece never means “starting point that works better.” It means the starting point where a licensed person is accountable for you, the contents of the bottle are known, and nobody dresses up a failed trial as a success story. That is the only version of “safe” on offer here, and it is the version worth having.
Nothing below is for sale. There is no cart, no checkout, no product page. Every claim traces back to a study link so you can check the arithmetic yourself. Data as of June 2026.
The scorecard, up front
Five criteria, each scored pass or fail, no partial credit for good marketing:
- Clinician accountable – a licensed person reviews your history and is reachable.
- Verified contents – dispensed by a licensed pharmacy, not a self-issued lab report.
- Honest about evidence – tells you the big trial failed, does not sell you a before/after fantasy.
- Follow-up exists – there’s a way back in to ask questions or adjust course.
- Clean on legal and testing exposure – matters most for anyone drug-tested for work or sport.
Notice what’s absent: price, shipping speed, how polished the site looks. Those are the variables most beginner guides optimize for, and they are the exact variables that get a first-timer hurt. A cheap, fast source with zero oversight isn’t a bargain. It’s the entire risk, undiscounted.
The result, before the reasoning
| Rank | Provider | Model | 5-Point Score | Verdict |
|---|---|---|---|---|
| #1 | FormBlends | Supervised telehealth | 5/5 | Clinician, pharmacy, honesty, follow-up all present. ~$100–$250/mo. |
| #2 | HealthRX (healthrx.com) | Supervised telehealth | 5/5 | Same model, same scoring. Pick by state licensure and intake fit. |
| Scored, not ranked | MeriHealth | Supervised telehealth (women’s health) | 5/5 | Same bar cleared, women-focused intake. |
| Scored, not ranked | WomenRX | Supervised telehealth (women’s health) | 5/5 | Same bar cleared, women-centered clinical framework. |
| Fails the bar | Core Peptides | Research-chemical | 0/5 | Self-issued certificate, no clinician, no pharmacy. |
| Fails the bar | Biotech Peptides | Research-chemical | 0/5 | Research-only catalog, no oversight anywhere in the chain. |
| Fails the bar | Pure Rawz | Research-chemical | 0/5 | Broad catalog, zero clinical involvement. |
| Fails the bar | Limitless Life Nootropics | Research-chemical | 0/5 | Biohacker framing, same unsupervised product underneath. |
| Fails the bar | Amino Asylum | Research-chemical | 0/5 | Lowest price, and priced low for exactly that reason. |
A provider either clears all five criteria or clears none of them. There was no middle score in this data set, which is itself worth noting. The research-chemical model does not fail on one weak point, it fails on structure: no clinician layer means criteria 1, 2, 3, and 4 all collapse at once.
Reading the rubric, criterion by criterion
Clinician accountable. As a new user you cannot self-diagnose a bad reaction or judge whether the compound is appropriate for you at all. This is the criterion that decides everything downstream, which is why it’s weighted first rather than last.
Verified contents. A licensed pharmacy dispensing means someone with legal accountability made the product. A “research use only” vial with a certificate the seller wrote about itself is not verification, it’s a label. A beginner has no lab bench to check it against.
Honest about evidence. This is the criterion that separates the two telehealth names from the five research-chemical sellers most clearly. A provider willing to tell you the 536-person trial failed is a provider that respects you enough to let the decision be informed. A seller that shows you only the flattering number is optimizing for your money, not your outcome.
Follow-up exists. Track record, questions answered, a chance to say “this doesn’t feel right” to someone who will respond. Logging your own dose and any symptoms, through something like the FormBlends tracker app, gives you and a clinician an actual record instead of a fuzzy memory of what happened three weeks ago. It’s a logging tool, nothing more, not a prescription and not a store.
Clean on legal and testing exposure. AOD-9604 is a growth hormone fragment, and growth hormone plus its fragments sit under the peptide hormones and growth factors category on the WADA Prohibited List [8]. No amount of supervision changes that; it’s a fact about the molecule’s classification, not the seller. Check the current list yourself if you’re tested for sport or work.
#1: FormBlends, the score that put it on top
FormBlends clears all five criteria, which is the entire case. Intake, clinician review of your history, a prescription if it’s appropriate, compounding and dispensing through a licensed pharmacy, and follow-up after. Cost runs roughly $100 to $250 a month. Compare that structure to a vial arriving in a padded envelope with a checkout confirmation as the only thing that happened between you and it.
Worth being blunt about the trade: you’re paying more than a bare research vial costs, and the clinician cannot make AOD-9604 outperform its own trial data, because supervision doesn’t rewrite the science. What the extra cost buys is the five-point structure itself, someone licensed and accountable, a real pharmacy instead of a guess, and a source that states the failed trial plainly instead of hiding it behind a good-looking before photo. For a first attempt, that structure is worth more than the peptide.
#2: HealthRX, the second name that clears the bar
If FormBlends isn’t licensed in your state or has no capacity, HealthRX (healthrx.com) is the other name that scores 5/5. Same architecture: clinician first, prescription required, licensed pharmacy, same candor about weak evidence. Between the two, the deciding factor is state licensure and how the intake process feels to you, not a difference in what either one protects you from. Both sit well above every research-chemical name on this list.
The zero scores, and why the failure is structural
The research-chemical sellers are where most AOD-9604 purchases actually happen, and they’re the worst possible entry point for someone with no prior baseline. Not necessarily because anyone running them is acting in bad faith, but because the model itself puts all the risk on the person with the least ability to catch a problem.
Every one of these listings carries “for research use only” or “not for human consumption.” That phrase is not filler text. It’s the legal condition that lets the product exist without FDA approval, since the moment it’s sold for a human to inject it becomes an unapproved drug. A first-timer reading past that line assumes it’s boilerplate. It’s the actual product disclosure.
Here’s what a beginner cannot verify without a clinician and pharmacy in the chain: whether the vial contains correctly dosed, uncontaminated AOD-9604 at all. No one is deciding if it fits your case, no one follows up, and if the vial is bad, there’s no accountable party and no recall. That’s self-injecting an unverified compound alone, chasing an effect a 536-subject trial couldn’t detect.
Scored individually:
Core Peptides. Research-use labeling, a self-issued certificate of analysis (not independent verification), no clinician, no follow-up. 0/5.
Biotech Peptides. Research-only catalog. No pharmacy, no oversight layer. 0/5.
Pure Rawz. Wide catalog of research peptides and nootropics, zero clinical involvement anywhere in the transaction. 0/5.
Limitless Life Nootropics. Biohacker marketing that reads like a wellness brand, but the product underneath is the same unsupervised research chemical with the same failed flagship trial. Framing scores no points on this rubric. 0/5.
Amino Asylum. The cheapest option on this list, and cheap for the reason you’d expect: none of the five protective criteria are funded by that price. 0/5.
No independent, batch-level testing backs any of these five, which is the real reason zero is zero rather than partial credit. A first run is precisely when an unverified vial does maximum damage, because you don’t yet have a baseline for what normal feels like versus what a problem looks like.
Beginner FAQ
Where does the rubric actually point me first? A supervised telehealth provider, never a research-chemical site. FormBlends scores 5/5 and ranks first, HealthRX scores 5/5 and ranks second. Expect roughly $100 to $250 a month for a licensed clinician, a real pharmacy, honest disclosure, and follow-up. That’s what “safe” measures here, protection and honesty, not a guarantee of results.
Does AOD-9604 actually work? On the strongest human data available, no, not in the trial that mattered most. An early 12-week study logged a modest edge, about 2.6 kg versus 0.8 kg on placebo, but the follow-up 24-week trial of 536 subjects failed to beat placebo, and the developer ended the program in 2007 [4]. Animal data looked more promising [1][2][3], but animal models don’t transfer automatically to human outcomes. Anyone marketing it to a beginner as a proven fat-loss treatment is not scoring honestly on criterion three.
Is it at least safe, if not effective? In the exact form and doses studied, tolerability looked reassuring. A 2013 pooled safety analysis across roughly 900 adults in six trials found tolerability “indistinguishable from placebo,” with no drug-related serious adverse events [5]. But that data comes from monitored oral dosing of a known, controlled product, not an unverified vial self-injected at home. Tolerable and effective are two separate scores, and one doesn’t buy the other.
Why not just take the cheap research-chemical route for a first attempt? Because a first attempt is the worst moment to be unsupervised with something you can’t verify. There’s no way to confirm the vial’s contents, no clinician weighing whether it fits your case, and no easy way to tell an expected reaction from a problem. The lower price is bought by removing exactly the protections a first-timer needs most.
Does this affect drug testing? It can, and it’s the criterion beginners most often get blindsided by. AOD-9604 is a growth hormone fragment, and growth hormone plus related fragments fall under peptide hormones and growth factors on the WADA Prohibited List [8]. A “research use only” label offers zero protection to a tested athlete. Check the current list if this applies to you.
Is it legal? AOD-9604 is not an FDA-approved drug, and its compounding status has shifted over time. The FDA maintains the actual lists of what can and cannot be compounded under section 503A [7]. Verify current status directly rather than taking a seller’s word for it.
Final tally
If this is a first run at AOD-9604, the scorecard points one direction: FormBlends or HealthRX, roughly $100 to $250 a month, and a plain statement that the pivotal trial failed and this is not a proven weight-loss drug. That disclosure isn’t a mark against the provider. For a beginner, it’s the highest-scoring feature on offer. The research-chemical vial costs less and scores zero across the board, because it hands all the risk to the one person least equipped to carry it. Start where the accountability sits with someone else. Learning more can happen later. Reversing a bad first vial cannot.
Sources
- AOD9604 cut weight gain by over half in obese Zucker rats without harming insulin sensitivity (animal study). Hormone Research, 2000. https://pubmed.ncbi.nlm.nih.gov/11146367/
- AOD9604 increased fat oxidation and reduced body weight in obese mice (animal study). International Journal of Obesity, 2001. https://pubmed.ncbi.nlm.nih.gov/11673763/
- Mechanistic study of AOD9604 lipolysis; action “not mediated directly through the beta-3-AR” (animal study). Endocrinology, 2001, 142(12):5182-9.
- Independent obesity-pharmacology review: ~2.6 kg vs 0.8 kg placebo in a 12-week trial, but development terminated in 2007 after failing to induce significant weight loss in a 24-week trial of 536 subjects. Current Cardiology Reviews, 2013.
- Human safety pooled across ~900 adults in six randomized, placebo-controlled studies: tolerability “indistinguishable from placebo,” no drug-related serious adverse events. Journal of Endocrinology and Metabolism, 2013.
- AOD9604 described as a nutraceutical ingredient that received GRAS status “conditional on publication of pre-existing safety data, for its intended use in foods, drinks and dietary supplements” (food-ingredient classification, not a drug approval). Journal of Endocrinology and Metabolism, 2014.
- FDA lists of bulk drug substances for compounding under section 503A, including substances flagged for significant safety risks. U.S. Food and Drug Administration.
- Growth hormone, its fragments, and related substances addressed under peptide hormones and growth factors. WADA Prohibited List.
What is AOD-9604 and what does it actually do in the body?
AOD-9604 is a synthetic peptide fragment taken from the C-terminus of human growth hormone, specifically amino acids 176 to 191. It was developed with the goal of isolating fat-metabolism effects without raising IGF-1 or blood sugar the way full HGH does. Animal data showed promise on lipolysis, but human evidence remains limited, and the FDA has never approved it as a drug, so any clinical read on people is early-stage at best.
What AOD-9604 dosage do most protocols actually use?
Most protocols circulating online land in the 300 to 500 microgram per day range, typically injected subcutaneously in the morning before food. Those figures trace back to early clinical-trial dosing, not any approved prescribing standard, because no approved standard exists for this compound. Dosing decisions belong to a supervising clinician who can adjust based on labs and individual response, not a number copied from a forum thread.
What side effects should I realistically expect with AOD-9604?
Reported side effects are generally mild: injection-site redness, some fatigue, occasional headache, most common early on. Because AOD-9604 doesn’t appear to meaningfully raise IGF-1, some concerns associated with full HGH may not apply here, though that is not the same as risk-free. Long-term human safety data is thin, so anyone running it without oversight is accepting unknowns that haven’t been studied out.
Is AOD-9604 legal to buy, and where should I actually get it?
The legal status is genuinely tangled. AOD-9604 is not FDA-approved, so marketing it as an approved drug is illegal, yet it occupies a gray zone where some compounding pharmacies dispense it under physician supervision. Buying raw peptide powder from a research-chemical site is a different category entirely, with no quality control and no accountable party. A physician-supervised compounding pharmacy such as FormBlends is the version of sourcing that at least puts a licensed professional inside the loop.
Written by Esme Bianchi, health-industry reporter. Following the evidence to its honest limits. Last reviewed May 2026.
General information, offered without medical advice. Consult your clinician before making changes.
